| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 35 | 2020 | 144 | 6.980 |
Why?
|
| Shock, Septic | 34 | 2020 | 69 | 3.900 |
Why?
|
| Ventilator Weaning | 9 | 2023 | 37 | 2.850 |
Why?
|
| Systemic Inflammatory Response Syndrome | 13 | 2018 | 27 | 2.810 |
Why?
|
| Respiration, Artificial | 18 | 2023 | 114 | 2.690 |
Why?
|
| Critical Illness | 11 | 2020 | 135 | 1.960 |
Why?
|
| Intensive Care Units | 13 | 2022 | 301 | 1.810 |
Why?
|
| Calcitonin | 6 | 2018 | 17 | 1.640 |
Why?
|
| Airway Extubation | 4 | 2022 | 10 | 1.620 |
Why?
|
| Humans | 126 | 2023 | 28408 | 1.450 |
Why?
|
| Pneumonia | 8 | 2018 | 77 | 1.340 |
Why?
|
| Critical Care | 15 | 2018 | 199 | 1.330 |
Why?
|
| Fluid Therapy | 5 | 2019 | 34 | 1.200 |
Why?
|
| Respiratory Insufficiency | 4 | 2022 | 52 | 1.040 |
Why?
|
| Consensus | 2 | 2016 | 98 | 1.030 |
Why?
|
| Respiratory Muscles | 2 | 2023 | 18 | 1.020 |
Why?
|
| Lung | 15 | 2023 | 170 | 0.960 |
Why?
|
| Biomarkers | 7 | 2021 | 596 | 0.900 |
Why?
|
| Hospitalization | 5 | 2018 | 323 | 0.860 |
Why?
|
| Algorithms | 6 | 2017 | 377 | 0.860 |
Why?
|
| Intubation, Intratracheal | 5 | 2023 | 99 | 0.840 |
Why?
|
| Adult | 39 | 2023 | 8097 | 0.840 |
Why?
|
| Antithrombin III | 2 | 2020 | 3 | 0.830 |
Why?
|
| Extracellular Traps | 1 | 2022 | 3 | 0.830 |
Why?
|
| Multiple Organ Failure | 12 | 2020 | 21 | 0.810 |
Why?
|
| Cystic Fibrosis | 2 | 2016 | 10 | 0.810 |
Why?
|
| Community-Acquired Infections | 9 | 2018 | 70 | 0.790 |
Why?
|
| Lung Diseases | 7 | 2020 | 47 | 0.740 |
Why?
|
| Thromboplastin | 2 | 2020 | 5 | 0.740 |
Why?
|
| Practice Guidelines as Topic | 7 | 2017 | 320 | 0.720 |
Why?
|
| Organ Dysfunction Scores | 2 | 2016 | 8 | 0.680 |
Why?
|
| Male | 48 | 2023 | 15273 | 0.670 |
Why?
|
| Acute Kidney Injury | 3 | 2019 | 47 | 0.660 |
Why?
|
| Rehydration Solutions | 1 | 2019 | 2 | 0.660 |
Why?
|
| Female | 45 | 2023 | 15708 | 0.660 |
Why?
|
| Sodium Chloride | 1 | 2019 | 36 | 0.630 |
Why?
|
| United States | 19 | 2018 | 2197 | 0.620 |
Why?
|
| Respiration | 2 | 2017 | 35 | 0.610 |
Why?
|
| Terminology as Topic | 4 | 2016 | 32 | 0.600 |
Why?
|
| Pneumonia, Ventilator-Associated | 7 | 2013 | 20 | 0.600 |
Why?
|
| Middle Aged | 40 | 2023 | 9254 | 0.600 |
Why?
|
| Anti-Bacterial Agents | 6 | 2016 | 378 | 0.590 |
Why?
|
| Pneumothorax | 7 | 2020 | 11 | 0.580 |
Why?
|
| Adrenal Insufficiency | 4 | 2017 | 6 | 0.580 |
Why?
|
| Vasoconstrictor Agents | 5 | 2019 | 28 | 0.580 |
Why?
|
| Pulmonary Ventilation | 2 | 2017 | 10 | 0.580 |
Why?
|
| Prospective Studies | 24 | 2023 | 1805 | 0.580 |
Why?
|
| Airway Resistance | 1 | 2017 | 5 | 0.570 |
Why?
|
| Decontamination | 1 | 2017 | 10 | 0.570 |
Why?
|
| Glucocorticoids | 2 | 2011 | 70 | 0.560 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2019 | 330 | 0.560 |
Why?
|
| Retrospective Studies | 9 | 2023 | 3609 | 0.560 |
Why?
|
| Aged | 32 | 2018 | 9262 | 0.550 |
Why?
|
| Length of Stay | 6 | 2019 | 328 | 0.540 |
Why?
|
| Clinical Chemistry Tests | 1 | 2016 | 5 | 0.540 |
Why?
|
| Advance Care Planning | 1 | 2016 | 12 | 0.510 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 41 | 0.510 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2017 | 117 | 0.510 |
Why?
|
| Pleural Effusion | 2 | 2011 | 12 | 0.510 |
Why?
|
| Dyspnea | 1 | 2016 | 42 | 0.500 |
Why?
|
| Palliative Care | 1 | 2016 | 109 | 0.470 |
Why?
|
| Lung Neoplasms | 4 | 2020 | 553 | 0.450 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 165 | 0.450 |
Why?
|
| Population Surveillance | 5 | 2015 | 110 | 0.440 |
Why?
|
| Inflammation | 5 | 2022 | 284 | 0.440 |
Why?
|
| Severity of Illness Index | 11 | 2021 | 986 | 0.440 |
Why?
|
| Haloperidol | 2 | 2003 | 6 | 0.430 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2017 | 80 | 0.430 |
Why?
|
| Torsades de Pointes | 2 | 2003 | 7 | 0.430 |
Why?
|
| Thorax | 3 | 2020 | 11 | 0.420 |
Why?
|
| Hospital Mortality | 4 | 2018 | 147 | 0.410 |
Why?
|
| Antipsychotic Agents | 2 | 2003 | 65 | 0.410 |
Why?
|
| Hydrocortisone | 5 | 2017 | 40 | 0.410 |
Why?
|
| Pain | 1 | 2016 | 405 | 0.400 |
Why?
|
| Norepinephrine | 2 | 2010 | 30 | 0.400 |
Why?
|
| Blood Pressure | 3 | 2011 | 207 | 0.390 |
Why?
|
| Peritoneal Dialysis | 2 | 2011 | 25 | 0.390 |
Why?
|
| Sound | 3 | 2015 | 13 | 0.360 |
Why?
|
| Cytokines | 4 | 2022 | 230 | 0.350 |
Why?
|
| Shock | 3 | 2019 | 11 | 0.350 |
Why?
|
| Risk Factors | 8 | 2021 | 2408 | 0.350 |
Why?
|
| Dopamine | 1 | 2010 | 87 | 0.330 |
Why?
|
| Pituitary-Adrenal System | 3 | 2017 | 13 | 0.330 |
Why?
|
| Prognosis | 8 | 2018 | 825 | 0.320 |
Why?
|
| Clinical Trials as Topic | 6 | 2011 | 239 | 0.300 |
Why?
|
| Carcinoma, Medullary | 1 | 2008 | 6 | 0.300 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2008 | 4 | 0.300 |
Why?
|
| Acoustics | 5 | 2020 | 19 | 0.300 |
Why?
|
| Flavoring Agents | 1 | 2008 | 3 | 0.300 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2008 | 15 | 0.300 |
Why?
|
| Hemodynamics | 8 | 2012 | 71 | 0.300 |
Why?
|
| Occupational Diseases | 1 | 2008 | 21 | 0.300 |
Why?
|
| Diarrhea | 1 | 2008 | 33 | 0.300 |
Why?
|
| Amyloid | 1 | 2008 | 56 | 0.300 |
Why?
|
| Thyroid Neoplasms | 1 | 2008 | 44 | 0.290 |
Why?
|
| Ventilators, Mechanical | 5 | 2023 | 23 | 0.290 |
Why?
|
| Gram-Negative Bacterial Infections | 4 | 2002 | 24 | 0.280 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2007 | 1 | 0.280 |
Why?
|
| Weight Loss | 1 | 2008 | 130 | 0.280 |
Why?
|
| Hyponatremia | 1 | 2007 | 9 | 0.270 |
Why?
|
| Methotrexate | 2 | 2005 | 36 | 0.270 |
Why?
|
| Neutrophils | 2 | 2022 | 110 | 0.270 |
Why?
|
| Choice Behavior | 1 | 2007 | 46 | 0.260 |
Why?
|
| Evidence-Based Medicine | 3 | 2017 | 196 | 0.260 |
Why?
|
| Protein Precursors | 3 | 2021 | 21 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2023 | 730 | 0.250 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2005 | 3 | 0.250 |
Why?
|
| Treatment Failure | 2 | 2017 | 163 | 0.250 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 17 | 0.250 |
Why?
|
| NF-kappa B | 2 | 2022 | 118 | 0.240 |
Why?
|
| Arsenicals | 1 | 2005 | 12 | 0.240 |
Why?
|
| Oxides | 1 | 2005 | 18 | 0.240 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2005 | 33 | 0.240 |
Why?
|
| Endotoxins | 4 | 2002 | 20 | 0.230 |
Why?
|
| Ventilator-Induced Lung Injury | 2 | 2013 | 3 | 0.220 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 2016 | 42 | 0.220 |
Why?
|
| Informed Consent | 1 | 2003 | 23 | 0.220 |
Why?
|
| Treatment Outcome | 9 | 2018 | 3615 | 0.210 |
Why?
|
| Tomography | 1 | 2023 | 13 | 0.210 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 190 | 0.210 |
Why?
|
| Respiratory Function Tests | 3 | 2016 | 36 | 0.210 |
Why?
|
| Atrophy | 1 | 2023 | 93 | 0.210 |
Why?
|
| Neutrophil Activation | 1 | 2022 | 7 | 0.210 |
Why?
|
| Echocardiography | 2 | 2014 | 114 | 0.210 |
Why?
|
| Respiratory Sounds | 4 | 2015 | 9 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2017 | 351 | 0.200 |
Why?
|
| beta-Glucans | 1 | 2022 | 24 | 0.200 |
Why?
|
| Silver Sulfadiazine | 1 | 2002 | 1 | 0.200 |
Why?
|
| Endotoxemia | 1 | 2002 | 27 | 0.200 |
Why?
|
| Survival Rate | 4 | 2011 | 356 | 0.190 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2002 | 40 | 0.190 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 331 | 0.190 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 492 | 0.190 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2002 | 46 | 0.190 |
Why?
|
| Methylprednisolone | 3 | 2017 | 22 | 0.190 |
Why?
|
| Adolescent | 6 | 2018 | 2307 | 0.190 |
Why?
|
| Animals | 14 | 2016 | 3780 | 0.180 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 932 | 0.180 |
Why?
|
| Young Adult | 5 | 2018 | 2069 | 0.180 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 53 | 0.180 |
Why?
|
| Pneumonia, Bacterial | 2 | 2018 | 11 | 0.180 |
Why?
|
| Time Factors | 8 | 2018 | 1490 | 0.180 |
Why?
|
| Clinical Competence | 1 | 2003 | 249 | 0.180 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2020 | 11 | 0.180 |
Why?
|
| Immunity, Innate | 1 | 2021 | 58 | 0.180 |
Why?
|
| Bacterial Infections | 4 | 2008 | 52 | 0.180 |
Why?
|
| Inflammation Mediators | 2 | 2000 | 68 | 0.180 |
Why?
|
| Intestines | 1 | 2021 | 99 | 0.180 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2020 | 6 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 134 | 0.180 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 23 | 0.180 |
Why?
|
| Computer Simulation | 3 | 2020 | 199 | 0.170 |
Why?
|
| Epidemiological Monitoring | 3 | 2016 | 8 | 0.170 |
Why?
|
| Odds Ratio | 2 | 2017 | 268 | 0.170 |
Why?
|
| Propensity Score | 2 | 2016 | 36 | 0.170 |
Why?
|
| Acute Disease | 4 | 2015 | 208 | 0.170 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 20 | 0.160 |
Why?
|
| Renal Replacement Therapy | 1 | 2019 | 23 | 0.160 |
Why?
|
| Midodrine | 1 | 2019 | 4 | 0.160 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 1998 | 4 | 0.160 |
Why?
|
| Nitric Oxide | 1 | 1999 | 81 | 0.160 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 309 | 0.160 |
Why?
|
| Serum Bactericidal Test | 1 | 2018 | 2 | 0.160 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 181 | 0.160 |
Why?
|
| Ibuprofen | 2 | 1988 | 12 | 0.160 |
Why?
|
| Tracheostomy | 1 | 2018 | 27 | 0.150 |
Why?
|
| Analysis of Variance | 3 | 2017 | 269 | 0.150 |
Why?
|
| Serogroup | 1 | 2018 | 2 | 0.150 |
Why?
|
| Antigens, Bacterial | 1 | 2018 | 4 | 0.150 |
Why?
|
| Pneumococcal Infections | 1 | 2018 | 7 | 0.150 |
Why?
|
| Incidence | 3 | 2015 | 773 | 0.150 |
Why?
|
| Body Mass Index | 2 | 2018 | 465 | 0.150 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2017 | 23 | 0.150 |
Why?
|
| Advisory Committees | 4 | 2017 | 25 | 0.140 |
Why?
|
| Work of Breathing | 1 | 2017 | 6 | 0.140 |
Why?
|
| Mucus | 1 | 2017 | 7 | 0.140 |
Why?
|
| Staphylococcus aureus | 2 | 2016 | 68 | 0.140 |
Why?
|
| Biofilms | 1 | 2017 | 16 | 0.140 |
Why?
|
| Single-Blind Method | 1 | 2017 | 110 | 0.140 |
Why?
|
| Risk Assessment | 3 | 2016 | 676 | 0.140 |
Why?
|
| Hospitals, University | 1 | 2017 | 28 | 0.140 |
Why?
|
| Punctures | 1 | 1997 | 10 | 0.140 |
Why?
|
| Catheters, Indwelling | 1 | 1997 | 24 | 0.140 |
Why?
|
| Diagnosis, Differential | 4 | 2018 | 372 | 0.140 |
Why?
|
| Auscultation | 2 | 2015 | 5 | 0.140 |
Why?
|
| Endovascular Procedures | 1 | 2017 | 34 | 0.140 |
Why?
|
| SOS1 Protein | 1 | 2016 | 4 | 0.140 |
Why?
|
| Patient Care Bundles | 1 | 2016 | 4 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2016 | 12 | 0.130 |
Why?
|
| Blood Gas Analysis | 2 | 2014 | 8 | 0.130 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2016 | 14 | 0.130 |
Why?
|
| Hospital Costs | 1 | 2017 | 64 | 0.130 |
Why?
|
| Patient Care Planning | 2 | 2016 | 52 | 0.130 |
Why?
|
| Survival Analysis | 11 | 2008 | 267 | 0.130 |
Why?
|
| Bone Density Conservation Agents | 1 | 2016 | 14 | 0.130 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2016 | 9 | 0.130 |
Why?
|
| Demography | 1 | 2016 | 73 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 65 | 0.130 |
Why?
|
| Dogs | 6 | 2002 | 184 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2004 | 192 | 0.130 |
Why?
|
| Tidal Volume | 2 | 2014 | 13 | 0.130 |
Why?
|
| Terminal Care | 1 | 2016 | 27 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2017 | 94 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 61 | 0.120 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 17 | 0.120 |
Why?
|
| Bronchoscopes | 1 | 1995 | 1 | 0.120 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 27 | 0.120 |
Why?
|
| Respiratory Rate | 1 | 2014 | 4 | 0.120 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2014 | 10 | 0.120 |
Why?
|
| Double-Blind Method | 10 | 2003 | 432 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2021 | 931 | 0.120 |
Why?
|
| Chronic Pain | 1 | 2016 | 111 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2016 | 358 | 0.110 |
Why?
|
| Forecasting | 2 | 2012 | 103 | 0.110 |
Why?
|
| Obesity | 1 | 2017 | 321 | 0.110 |
Why?
|
| Protein C | 2 | 2004 | 10 | 0.110 |
Why?
|
| Public Health Surveillance | 1 | 2013 | 11 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 155 | 0.110 |
Why?
|
| Injections, Intravenous | 2 | 2003 | 31 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2022 | 447 | 0.100 |
Why?
|
| Polyethylene Glycols | 2 | 2008 | 43 | 0.100 |
Why?
|
| Hypothermia | 1 | 1992 | 6 | 0.100 |
Why?
|
| Catheterization, Central Venous | 1 | 1992 | 35 | 0.100 |
Why?
|
| Ultrasonography, Doppler | 1 | 2012 | 16 | 0.100 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2023 | 9 | 0.100 |
Why?
|
| Cause of Death | 3 | 2018 | 64 | 0.100 |
Why?
|
| Chicago | 2 | 2015 | 939 | 0.100 |
Why?
|
| Hypotension | 2 | 1989 | 29 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 3 | 2000 | 199 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2011 | 47 | 0.090 |
Why?
|
| Pulmonary Alveoli | 3 | 1997 | 29 | 0.090 |
Why?
|
| Quality of Life | 1 | 2016 | 659 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2011 | 102 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2011 | 61 | 0.090 |
Why?
|
| APACHE | 5 | 2021 | 31 | 0.090 |
Why?
|
| Enzyme Inhibitors | 2 | 2002 | 120 | 0.090 |
Why?
|
| Bronchoscopy | 2 | 2008 | 34 | 0.090 |
Why?
|
| Inpatients | 2 | 2015 | 149 | 0.090 |
Why?
|
| Tachycardia, Sinus | 1 | 2010 | 2 | 0.090 |
Why?
|
| Vasopressins | 1 | 2010 | 8 | 0.090 |
Why?
|
| Macrophages | 2 | 1991 | 108 | 0.090 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 4853 | 0.080 |
Why?
|
| Biopsy | 2 | 2008 | 220 | 0.080 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2010 | 73 | 0.080 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 1989 | 2 | 0.080 |
Why?
|
| Cross Infection | 2 | 2010 | 282 | 0.080 |
Why?
|
| Recombinant Proteins | 4 | 2003 | 213 | 0.080 |
Why?
|
| Immunoglobulin Fc Fragments | 2 | 2021 | 6 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2021 | 1926 | 0.080 |
Why?
|
| Signal Processing, Computer-Assisted | 3 | 2005 | 33 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 1999 | 31 | 0.080 |
Why?
|
| Mycoses | 1 | 2008 | 23 | 0.080 |
Why?
|
| Diacetyl | 1 | 2008 | 1 | 0.080 |
Why?
|
| Food Industry | 1 | 2008 | 1 | 0.080 |
Why?
|
| Stethoscopes | 2 | 2005 | 3 | 0.080 |
Why?
|
| Random Allocation | 4 | 1989 | 129 | 0.080 |
Why?
|
| Occupational Exposure | 1 | 2008 | 17 | 0.080 |
Why?
|
| Models, Anatomic | 2 | 2020 | 39 | 0.070 |
Why?
|
| Respiratory Care Units | 1 | 1988 | 3 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 517 | 0.070 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2017 | 5 | 0.070 |
Why?
|
| Hemoglobins | 1 | 2008 | 78 | 0.070 |
Why?
|
| ROC Curve | 2 | 2018 | 144 | 0.070 |
Why?
|
| Therapeutic Irrigation | 2 | 1986 | 56 | 0.070 |
Why?
|
| Arginine Vasopressin | 1 | 2007 | 2 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 362 | 0.070 |
Why?
|
| Benzazepines | 1 | 2007 | 4 | 0.070 |
Why?
|
| Azepines | 1 | 2007 | 3 | 0.070 |
Why?
|
| Benzamides | 1 | 2007 | 15 | 0.070 |
Why?
|
| Pyrroles | 1 | 2007 | 24 | 0.070 |
Why?
|
| Radiography, Thoracic | 3 | 2021 | 28 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 2008 | 202 | 0.070 |
Why?
|
| Receptors, Interleukin-1 | 2 | 1997 | 4 | 0.060 |
Why?
|
| Sialoglycoproteins | 2 | 1997 | 9 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2011 | 72 | 0.060 |
Why?
|
| Medical Errors | 1 | 2005 | 28 | 0.060 |
Why?
|
| Positive-Pressure Respiration | 4 | 1998 | 11 | 0.060 |
Why?
|
| Sus scrofa | 2 | 2015 | 7 | 0.060 |
Why?
|
| Liver Cirrhosis | 1 | 2005 | 45 | 0.060 |
Why?
|
| Foreign Bodies | 1 | 2005 | 30 | 0.060 |
Why?
|
| Esophagus | 3 | 2005 | 65 | 0.060 |
Why?
|
| Prevalence | 3 | 2016 | 467 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 120 | 0.060 |
Why?
|
| Hemofiltration | 1 | 2004 | 8 | 0.060 |
Why?
|
| Plasma Exchange | 1 | 2004 | 12 | 0.060 |
Why?
|
| Sound Spectrography | 3 | 2015 | 21 | 0.060 |
Why?
|
| Monitoring, Physiologic | 2 | 1995 | 76 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2003 | 111 | 0.060 |
Why?
|
| Anti-Infective Agents | 1 | 2004 | 36 | 0.060 |
Why?
|
| Magnesium Sulfate | 1 | 2003 | 8 | 0.050 |
Why?
|
| Lipopolysaccharides | 3 | 2011 | 115 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2018 | 439 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2015 | 199 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2004 | 59 | 0.050 |
Why?
|
| Platelet Activating Factor | 1 | 2003 | 8 | 0.050 |
Why?
|
| Phospholipases A | 1 | 2003 | 7 | 0.050 |
Why?
|
| Hyperglycemia | 1 | 2003 | 32 | 0.050 |
Why?
|
| Calcitonin Gene-Related Peptide | 2 | 2015 | 11 | 0.050 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2023 | 3 | 0.050 |
Why?
|
| Insulin | 1 | 2003 | 90 | 0.050 |
Why?
|
| Suction | 1 | 2023 | 40 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 49 | 0.050 |
Why?
|
| Infusions, Intravenous | 3 | 2017 | 53 | 0.050 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1982 | 6 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2023 | 49 | 0.050 |
Why?
|
| Syk Kinase | 1 | 2022 | 10 | 0.050 |
Why?
|
| Pentostatin | 1 | 2002 | 1 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2003 | 111 | 0.050 |
Why?
|
| Logistic Models | 3 | 2016 | 395 | 0.050 |
Why?
|
| Limulus Test | 1 | 2002 | 4 | 0.050 |
Why?
|
| Lectins, C-Type | 1 | 2022 | 46 | 0.050 |
Why?
|
| Capillary Permeability | 1 | 2002 | 30 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 49 | 0.050 |
Why?
|
| Fiber Optic Technology | 2 | 1995 | 7 | 0.050 |
Why?
|
| Glycomics | 1 | 2021 | 3 | 0.050 |
Why?
|
| Haptoglobins | 1 | 2021 | 4 | 0.050 |
Why?
|
| Metabolomics | 1 | 2021 | 17 | 0.050 |
Why?
|
| Tight Junctions | 1 | 2021 | 24 | 0.050 |
Why?
|
| Receptors, Fc | 1 | 2021 | 9 | 0.050 |
Why?
|
| Complement Activation | 1 | 2021 | 10 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2021 | 35 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2021 | 27 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 17 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 19 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2021 | 44 | 0.050 |
Why?
|
| Permeability | 1 | 2021 | 120 | 0.050 |
Why?
|
| Sarcopenia | 1 | 2021 | 31 | 0.040 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2020 | 3 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2020 | 81 | 0.040 |
Why?
|
| Finite Element Analysis | 1 | 2020 | 29 | 0.040 |
Why?
|
| Ischemia | 1 | 2000 | 23 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 166 | 0.040 |
Why?
|
| Epoprostenol | 2 | 1998 | 7 | 0.040 |
Why?
|
| Escherichia coli | 3 | 1991 | 56 | 0.040 |
Why?
|
| omega-N-Methylarginine | 1 | 1999 | 3 | 0.040 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1999 | 7 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 1999 | 11 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 23 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 593 | 0.040 |
Why?
|
| Cardiovascular System | 1 | 1999 | 15 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 1999 | 45 | 0.040 |
Why?
|
| Pulmonary Surfactants | 2 | 1998 | 5 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 260 | 0.040 |
Why?
|
| Netherlands | 1 | 2018 | 25 | 0.040 |
Why?
|
| Airway Obstruction | 2 | 1997 | 20 | 0.040 |
Why?
|
| Urinalysis | 1 | 2018 | 9 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 13 | 0.040 |
Why?
|
| Mice | 3 | 2016 | 1461 | 0.040 |
Why?
|
| Life Tables | 1 | 1998 | 4 | 0.040 |
Why?
|
| Fibrinolysis | 1 | 1998 | 7 | 0.040 |
Why?
|
| Neuroendocrine Cells | 1 | 2017 | 1 | 0.040 |
Why?
|
| Cosyntropin | 1 | 2017 | 3 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2017 | 18 | 0.040 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2017 | 7 | 0.040 |
Why?
|
| Hormones | 1 | 2017 | 11 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2011 | 539 | 0.040 |
Why?
|
| Viruses | 1 | 2017 | 6 | 0.040 |
Why?
|
| Antimicrobial Stewardship | 1 | 2017 | 11 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 45 | 0.040 |
Why?
|
| Thoracostomy | 1 | 1997 | 2 | 0.040 |
Why?
|
| Immunoassay | 1 | 2017 | 40 | 0.040 |
Why?
|
| Safety | 1 | 1997 | 45 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 475 | 0.030 |
Why?
|
| Enterobacteriaceae | 1 | 2017 | 43 | 0.030 |
Why?
|
| Interleukin-1 | 2 | 1994 | 49 | 0.030 |
Why?
|
| Radiography | 2 | 2015 | 639 | 0.030 |
Why?
|
| Drainage | 1 | 1997 | 49 | 0.030 |
Why?
|
| Time-Lapse Imaging | 1 | 2016 | 5 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 13 | 0.030 |
Why?
|
| A549 Cells | 1 | 2016 | 10 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2016 | 15 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1996 | 27 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1996 | 31 | 0.030 |
Why?
|
| Syndrome | 3 | 1993 | 82 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 102 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 82 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 781 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 112 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2016 | 178 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 249 | 0.030 |
Why?
|
| Tennessee | 1 | 2015 | 9 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 500 | 0.030 |
Why?
|
| Acceleration | 1 | 2015 | 21 | 0.030 |
Why?
|
| Absorption, Radiation | 1 | 2015 | 1 | 0.030 |
Why?
|
| Bronchi | 2 | 2005 | 12 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1995 | 16 | 0.030 |
Why?
|
| Seasons | 1 | 2015 | 24 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 1995 | 20 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 89 | 0.030 |
Why?
|
| Scattering, Radiation | 1 | 2015 | 37 | 0.030 |
Why?
|
| Manometry | 1 | 1995 | 17 | 0.030 |
Why?
|
| Hemoptysis | 1 | 1995 | 7 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2017 | 689 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 43 | 0.030 |
Why?
|
| Phosphorylcholine | 1 | 1994 | 5 | 0.030 |
Why?
|
| Asthma | 1 | 2017 | 162 | 0.030 |
Why?
|
| Fatty Alcohols | 1 | 1994 | 7 | 0.030 |
Why?
|
| Clinical Protocols | 2 | 2010 | 60 | 0.030 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2016 | 116 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 1993 | 79 | 0.030 |
Why?
|
| Health Policy | 1 | 2013 | 50 | 0.030 |
Why?
|
| Models, Biological | 1 | 2015 | 326 | 0.030 |
Why?
|
| Patient Safety | 1 | 2013 | 54 | 0.030 |
Why?
|
| Subclavian Vein | 1 | 1992 | 1 | 0.030 |
Why?
|
| Femoral Vein | 1 | 1992 | 2 | 0.030 |
Why?
|
| Jugular Veins | 1 | 1992 | 2 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 1991 | 14 | 0.030 |
Why?
|
| Child | 1 | 2017 | 1421 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 372 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1995 | 263 | 0.020 |
Why?
|
| Liver | 2 | 1992 | 160 | 0.020 |
Why?
|
| Biotin | 1 | 2011 | 7 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2011 | 67 | 0.020 |
Why?
|
| Canada | 1 | 2011 | 51 | 0.020 |
Why?
|
| Europe | 1 | 2011 | 66 | 0.020 |
Why?
|
| Barotrauma | 2 | 1998 | 3 | 0.020 |
Why?
|
| Acidosis, Respiratory | 1 | 1990 | 1 | 0.020 |
Why?
|
| Dialysis Solutions | 1 | 1990 | 5 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 148 | 0.020 |
Why?
|
| Lung Injury | 2 | 1998 | 10 | 0.020 |
Why?
|
| Glucose | 1 | 1990 | 55 | 0.020 |
Why?
|
| Resuscitation | 1 | 2010 | 15 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2011 | 308 | 0.020 |
Why?
|
| Arachidonic Acids | 1 | 1989 | 8 | 0.020 |
Why?
|
| Body Temperature | 1 | 1989 | 50 | 0.020 |
Why?
|
| Cardiac Output | 1 | 1989 | 14 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 1989 | 27 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 1988 | 32 | 0.020 |
Why?
|
| Oxygen | 2 | 1992 | 73 | 0.020 |
Why?
|
| Infection Control | 1 | 2008 | 166 | 0.020 |
Why?
|
| Corynebacterium Infections | 1 | 1986 | 1 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 1986 | 21 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 1986 | 45 | 0.020 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 1997 | 15 | 0.020 |
Why?
|
| Lung Diseases, Fungal | 1 | 1985 | 10 | 0.020 |
Why?
|
| Blastomycosis | 1 | 1985 | 21 | 0.020 |
Why?
|
| Bacterial Translocation | 1 | 2005 | 23 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 1985 | 97 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2005 | 32 | 0.010 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2005 | 53 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 1986 | 158 | 0.010 |
Why?
|
| Trachea | 1 | 2005 | 49 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1986 | 619 | 0.010 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2003 | 1 | 0.010 |
Why?
|
| Respiratory Therapy | 1 | 1983 | 14 | 0.010 |
Why?
|
| Mediastinoscopy | 1 | 1982 | 7 | 0.010 |
Why?
|
| Skin Tests | 1 | 1982 | 8 | 0.010 |
Why?
|
| Sputum | 1 | 1982 | 21 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1982 | 43 | 0.010 |
Why?
|
| Adenosine Deaminase | 1 | 2002 | 1 | 0.010 |
Why?
|
| Adenosine Deaminase Inhibitors | 1 | 2002 | 1 | 0.010 |
Why?
|
| Clinical Laboratory Techniques | 1 | 1982 | 29 | 0.010 |
Why?
|
| Leukocytes | 1 | 2002 | 38 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 106 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 1983 | 64 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2003 | 352 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1982 | 371 | 0.010 |
Why?
|
| Mediastinal Emphysema | 1 | 1997 | 1 | 0.010 |
Why?
|
| Pleural Diseases | 1 | 1997 | 2 | 0.010 |
Why?
|
| Pulmonary Atelectasis | 1 | 1997 | 4 | 0.010 |
Why?
|
| Air | 1 | 1997 | 4 | 0.010 |
Why?
|
| Bronchiectasis | 1 | 1997 | 2 | 0.010 |
Why?
|
| Cysts | 1 | 1997 | 18 | 0.010 |
Why?
|
| Radiography, Interventional | 1 | 1997 | 23 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 1997 | 44 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1996 | 94 | 0.010 |
Why?
|
| Medical Records | 1 | 1995 | 34 | 0.010 |
Why?
|
| Catheterization | 1 | 1995 | 45 | 0.010 |
Why?
|
| Intubation | 1 | 1994 | 6 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1994 | 36 | 0.010 |
Why?
|
| Pressure | 1 | 1995 | 64 | 0.010 |
Why?
|
| Aerosols | 1 | 1994 | 23 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1994 | 18 | 0.010 |
Why?
|
| Disease Progression | 1 | 1997 | 717 | 0.010 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1993 | 55 | 0.010 |
Why?
|
| Pulmonary Medicine | 1 | 1992 | 1 | 0.010 |
Why?
|
| Platelet Count | 1 | 1992 | 16 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1992 | 149 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1991 | 20 | 0.010 |
Why?
|
| Risk | 1 | 1992 | 205 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1991 | 176 | 0.010 |
Why?
|
| Societies, Medical | 1 | 1992 | 154 | 0.010 |
Why?
|
| Thromboxane-A Synthase | 1 | 1989 | 1 | 0.010 |
Why?
|
| Thromboxane A2 | 1 | 1989 | 2 | 0.010 |
Why?
|
| Bilirubin | 1 | 1989 | 11 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 1989 | 24 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1989 | 19 | 0.010 |
Why?
|
| Thermodilution | 1 | 1989 | 6 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1989 | 20 | 0.000 |
Why?
|
| Aspartate Aminotransferases | 1 | 1989 | 15 | 0.000 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1989 | 27 | 0.000 |
Why?
|
| Heart Diseases | 1 | 1989 | 70 | 0.000 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1990 | 192 | 0.000 |
Why?
|
| Kidney | 1 | 1989 | 175 | 0.000 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1985 | 9 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1985 | 66 | 0.000 |
Why?
|
| Antifungal Agents | 1 | 1985 | 43 | 0.000 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1985 | 35 | 0.000 |
Why?
|